Data from EMC - Curated by Toby Galbraith - Last updated 11 July 2017

Licensing authority

EMA (European Medicines Agency)

Indication(s)

Sebivo is indicated for the treatment of chronic hepatitis B in adult patients with compensated liver disease and evidence of viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis.

Initiation of Sebivo treatment should only be considered when the use of an alternative antiviral agent with a higher genetic barrier to resistance is not available or appropriate.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Transplantation

See information on best practice in solid organ transplantation, and expert discussions on related hot topics.

Visit Transplantation


Fluid Management

Are you up-to-date with the latest evidence of effective procedures for fluid management?

Visit Fluid Management


Related Content

More information

Category Value
Agency product number EMEA/H/C/000713
Orphan designation No
Date First Approved 24-04-2007
Type Medicinal product subject to restricted medical prescription
Marketing authorisation holder Novartis Europharm Ltd.